HIV Clinic-Based Extended Release Naltrexone versus Treatment as Usual for People with HIV and Opioid Use Disorder: A Non-Blinded, Randomised Non-inferiority Trial

Original research
by
Korthuis, P. Todd et al

Release Date

2022

Geography

USA

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

Opioid agonist medications for treatment of opioid use disorder (OUD) can improve human immunodeficiency virus (HIV) outcomes and reduce opioid use. We tested whether outpatient antagonist treatment with naltrexone could achieve similar results.

Findings/Key points

Supportive, but not conclusive, evidence that HIV clinic-based extended-release naltrexone is not inferior to treatment as usual for facilitating HIV viral suppression. Participants who initiated extended-release naltrexone used less opioids than those who received treatment as usual.

Design/methods

Open-label, non-inferiority randomized trial (n=114)

doi.org

Keywords

Outcomes
Illegal drugs
About PWUD